{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03262935: Phase 3 Interventional Completed Metastatic Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:adintrevimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vensobafusp alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efparepoetin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:bempikibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:delpacibart zotadirsen [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:nasaruplase gamma [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:uliledlimab [INN]
Source URL:
Class:
PROTEIN